This CME activity reviews the mechanism of action, efficacy, and safety of targeted agents approved for the management of severe, uncontrolled asthma with Type 2 inflammation and those in late-stage development.

Review evidence-based therapeutic options for the management of motor fluctuations and dyskinesia in PD and discuss new and emerging levodopa and non-levodopa-based therapies.

Utilize evidence-based recommendations to individualize pharmacologic treatment options for patients with T2DM

Provide comprehensive strategies for earlier diagnosis using effective communication techniques that lead to appropriate treatment and better quality of life for patients with functional GI disorders.

Summary of guideline updates, clinical expertise, and new or emerging treatments for major chronic illnesses encountered daily in family practice medicine.

Formulate management plans and review emerging strategies for adverse events associated with PARP inhibitors in the frontline, maintenance setting.

Advancements in novel therapies and technologies, lifestyle medicine, multidisciplinary approaches that are driving improvements in outcomes and quality, and cardiovascular (CVD)/metabolic disease prevention.

Role of PCSK9 Inhibitors in the Management of Patients with Familial Hypercholesterolemia Recognize the warning signs of Familial Hypercholesterolemia (FH) in patients who present with high cholesterol and learn to devise medical treatment plans in line with evidence-based guidelines for LDL-C management

Optimizing the Diagnosis and Management Through Multi-Disciplinary, Patient-Centered Care